Mismatch repair-mediated G2/M arrest by 6-thioguanine involves the ATR–Chk1 pathway
Section snippets
Materials and methods
Cells and cell culture. HeLa cells, a human cervical carcinoma cell line which is known to be MMR-proficient [16], were grown in RPMI 1640 medium supplemented with 10% fetal calf serum in a humidified atmosphere of 10% CO2 and 90% air at 37 °C. Human ATM−/− fibroblast cells (FT169A) and its wild-type ATM transfected cells (ATM+, YZ5) (generous gifts of Dr. Y. Shiloh) [17] were also grown under the conditions described above.
Transfection of siRNA. Transfection was performed with oligofectamine as
Chk1 and Chk2 are phosphorylated during 6-TG treatment
We used an antibody against phosphorylated serine 317 of Chk1 to examine the involvement of the checkpoint kinase Chk1 in HeLa cells following 6-TG treatment. Phosphorylation of serine 317 is essential for the full activation of Chk1 [23]. Phosphorylation of Chk1 was gradually increased in HeLa cells during 4 days of treatment with 3 μM 6-TG (Fig. 1). The extent of Chk1 phosphorylation is temporally correlated with the 6-TG-induced G2/M peak induction (Fig. 2B), similar to our recently published
Discussion
In this study, we demonstrate that the ATR–Chk1 pathway participates in a G2/M cell cycle checkpoint activation by 6-TG-induced DNA mismatches. We show that a reduction of ATR kinase by siRNA strongly inhibits the G2/M checkpoint response and results in an induction of apoptosis after 6-TG treatment (Fig. 2). Our data also show that 6-TG treatment results in a critical phosphorylation of Chk1 (Fig. 1). Consistently, a reduction of Chk1 kinase results in failure of the formation of a major G2/M
Acknowledgements
We thank Mr. Michael Sramkoski and Dr. James Jacobberger of CWRU for flow cytometry techniques. This work was supported by NIH Grant CA84578 (T.J.K., PI), and the flow cytometry core of the Case Comprehensive Cancer Center at University Hospitals of Cleveland/CWRU (P30 CA43703).
References (30)
- et al.
Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines
Eur. J. Cancer
(2000) - et al.
Requirement for PCNA in DNA mismatch repair at a step preceding DNA resynthesis
Cell
(1996) - et al.
Threonine 68 of Chk2 is phosphorylated at sites of DNA strand breaks
J. Biol. Chem.
(2001) - et al.
Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor
J. Biol. Chem.
(2003) - et al.
Targeting DNA mismatch repair for radiosensitization
Semin. Radiat. Oncol.
(2001) - et al.
The role of DNA mismatch repair in drug resistance
Clin. Cancer Res.
(1998) The role of mismatch repair in DNA damage-induced apoptosis
Oncol. Res.
(1999)- et al.
Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses
Cancer Res.
(2001) - et al.
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
N. Engl. J. Med.
(2003) - et al.
Microsatellite instability as a potential marker for poor prognosis in adult T cell leukemia/lymphoma
Leuk. Lymphoma
(1999)